Who are DAPT on-target's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Conventional DAPT, Double antiplatelet therapy, rivaroxaban and ticagrel therapy, Asprin, Cilostazol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dapt-on-target.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DAPT on-target — Competitive Intelligence Brief

DAPT on-target (DAPT on-target) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet combination therapy. Area: Cardiovascular.

marketed Antiplatelet combination therapy Cyclooxygenase (COX) and P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

DAPT on-target (DAPT on-target) — Kaiser Franz Josef Hospital. DAPT (dual antiplatelet therapy) on-target inhibits platelet aggregation through simultaneous blockade of multiple platelet activation pathways to prevent thrombotic events.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DAPT on-target TARGET	DAPT on-target	Kaiser Franz Josef Hospital	marketed	Antiplatelet combination therapy	Cyclooxygenase (COX) and P2Y12 receptor
Conventional DAPT	Conventional DAPT	Zunyi Medical College	marketed	Antiplatelet combination therapy	Cyclooxygenase (COX) and P2Y12 receptor
Double antiplatelet therapy	Double antiplatelet therapy	University Hospital, Bordeaux	marketed	Antiplatelet combination therapy	Cyclooxygenase (COX) and P2Y12 receptor
rivaroxaban and ticagrel therapy	rivaroxaban and ticagrel therapy	Beijing Anzhen Hospital	marketed	Anticoagulant and antiplatelet combination therapy	Factor Xa (rivaroxaban); P2Y12 receptor (ticagrelor)
Asprin, Cilostazol	Asprin, Cilostazol	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	phase 3	Antiplatelet combination therapy	COX-1 (aspirin); PDE-3 (cilostazol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet combination therapy class)

Kaiser Franz Josef Hospital · 1 drug in this class
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · 1 drug in this class
University Hospital, Bordeaux · 1 drug in this class
Zunyi Medical College · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DAPT on-target — Competitive Intelligence Brief. https://druglandscape.com/ci/dapt-on-target. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab